Launch week offerEnds in00h00m00s

annual Promonthly Pro

Samantha Martin

Head of Research

Drug Safety Research Unit

United Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United Kingdom

Articles (8)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (7)

Estel Plana

Health Solutions

UNITED STATES

View details

Debabrata Roy

Head of Epidemiology and Research

Drug Safety Research Unit

UNITED KINGDOM

View details

Maria Giner-Soriano

Collaborator teacher (Professora col·laboradora)

Universitat de Girona

SPAIN

View details

Joan Forns

Health Solutions

UNITED STATES

View details

Cristina Rebordosa

Health Solutions

UNITED STATES

View details

David Martínez

Health Solutions

UNITED STATES

View details

G. Niklas Norén

Chief Science Officer

Internal Displacement Monitoring Centre

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Samantha Martin

Research Interests

Make your next move.

Explore related searches

Articles (8)

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222

Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group

Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study

Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance

From a pyramid to an amphitheatre (triangle to circle): embracing the totality of evidence for the postmarketing evaluation of the safety of therapeutic interventions

Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof‐of‐Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action

A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions.

The International Working Group on New Developments in Pharmacovigilance: Advancing Methods and Communication in Pharmacovigilance.

Collaborators (7)

Estel Plana

Debabrata Roy

Maria Giner-Soriano

Joan Forns

Cristina Rebordosa

David Martínez

G. Niklas Norén

Make your next move.